The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non‐alcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The prevalence of non-alcoholic fatty liver disease (NAFLD) continues to increase dramatically, and there is no approved medication for its treatment. Recently, we predicted the underlying molecular mechanisms involved in the progression of NAFLD using network analysis and identified metabolic cofactors that might be beneficial as supplements to decrease human liver fat. Here, we first assessed the tolerability of the combined metabolic cofactors including l-serine, N-acetyl-l-cysteine (NAC), nicotinamide riboside (NR), and l-carnitine by performing a 7-day rat toxicology study. Second, we performed a human calibration study by supplementing combined metabolic cofactors and a control study to study the kinetics of these metabolites in the plasma of healthy subjects with and without supplementation. We measured clinical parameters and observed no immediate side effects. Next, we generated plasma metabolomics and inflammatory protein markers data to reveal the acute changes associated with the supplementation of the metabolic cofactors. We also integrated metabolomics data using personalized genome-scale metabolic modeling and observed that such supplementation significantly affects the global human lipid, amino acid, and antioxidant metabolism. Finally, we predicted blood concentrations of these compounds during daily long-term supplementation by generating an ordinary differential equation model and liver concentrations of serine by generating a pharmacokinetic model and finally adjusted the doses of individual metabolic cofactors for future human clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745 · cited 1×
“Hepatic steatosis (HS) is defined as the accumulation of large vacuoles of triglycerides in the liver (> 5.5% tissue weight) due to an imbalance between lipid deposition and lipid removal from the liver (Solinas et al, 2015; Francque et al, 2016; Samuel & Shulman, 2018).”
BackgroundInfluentialNicotinamide riboside is uniquely and orally bioavailable in mice and humans
Trammell, S. A. J., Schmidt, M. S., Weidemann, B. J., Redpath, P., Jaksch, F., Dellinger, R. W., Li, Z., Abel, E. D., Migaud, M. E., & Brenner, C. (2016) · Nature Communications · doi:10.1038/ncomms12948 · Cited by 697 · cited 1×
“Trammell et al (Trammell et al, 2016) supplemented 1 g/day NR for 7 days to one subject.”
BackgroundIncreased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease
Dushay, J., Chui, P. C., Gopalakrishnan, G. S., Varela–Rey, M., Crawley, M., Fisher, F. M., Badman, M. K., Martinez–Chantar, M. L., & Maratos–Flier, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.054 · Cited by 607
Determinants of Fibrosis Progression and Regression in NASH
Schuppan, D., Surabattula, R., & Wang, X. Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.012 · Cited by 479 · cited 1×
“The decreased plasma level of MMP1 has been associated with NAFLD in previous studies (Mahmoud et al, 2012; Schuppan et al, 2018).”
BackgroundThe gut microbiota modulates host amino acid and glutathione metabolism in mice
Mardinoglu, A., Shoaie, S., Bergentall, M., Ghaffari, P., Zhang, C., Larsson, E., Bäckhed, F., & Nielsen, J. (2015) · Molecular Systems Biology · doi:10.15252/msb.20156487 · Cited by 383
Self-citation
Cited by
Benedé-Ubieto, R., Cubero, F. J., & Nevzorova, Y. A. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2331460 · Cited by 242
“123,124 Moreover, multi-ingredient supplementation administrated to diet-induced MASLD mice is able to ameliorate gut morphological changes, increase epithelial cell proliferation and the number of goblet cells, restore TJ barrier integrity, and reduce intestinal inflammation by improving…”
BackgroundCombined Metabolic Activators Accelerates Recovery in Mild‐to‐Moderate COVID‐19
Altay, O., Arif, M., Li, X., Yang, H., Aydın, M., Alkurt, G., Kim, W., Akyol, D., Zhang, C., Dinler‐Doganay, G., et al. (2021) · Advanced Science · doi:10.1002/advs.202101222 · Cited by 88
Self-citationYulug, B., Altay, O., Li, X., Hanoglu, L., Cankaya, S., Lam, S., Velioglu, H. A., Yang, H., Coskun, E., Idil, E., et al. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00336-2 · Cited by 79
Self-citationRole of Carnitine in Non-alcoholic Fatty Liver Disease and Other Related Diseases: An Update
Li, N., & Zhao, H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.689042 · Cited by 79
Genome-scale models in human metabologenomics
Mardinoglu, A., & Palsson, B. Ø. (2025) · Nature Reviews Genetics · doi:10.1038/s41576-024-00768-0 · Cited by 54
Metadata
- Authors
- Zhang, C., Bjornson, E., Arif, M., Tebani, A., Lovric, A., Benfeitas, R., Ozcan, M., Juszczak, K., Kim, W., Kim, J. T., Bidkhori, G., Ståhlman, M., Bergh, P., Adiels, M., Turkez, H., Taskinen, M., Bosley, J., Marschall, H., Nielsen, J., Uhlén, M., Borén, J., & Mardinoglu, A.
- Venue
- Molecular Systems Biology
- Published
- 2020-04
- Volume
- 16
- Issue
- 4
- Pages
- e9495-e9495
- ISSN
- 1744-4292 (ISSN-L)
- OpenAlex
- W3018889811
- Cited by
- 44
- References
- 5
- FWCI
- 4.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non‐alcoholic fatty liver disease. https://app.cochat.ai/papers/10.15252/msb.209495
- The paper
- Zhang, C., Bjornson, E., Arif, M., Tebani, A., Lovric, A., Benfeitas, R., Ozcan, M., Juszczak, K., Kim, W., Kim, J. T., Bidkhori, G., Ståhlman, M., Bergh, P., Adiels, M., Turkez, H., Taskinen, M., Bosley, J., Marschall, H., Nielsen, J., . . . Mardinoglu, A. (2020). The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non‐alcoholic fatty liver disease. Molecular Systems Biology. https://doi.org/10.15252/msb.209495
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.